Timeline This is a timeline of important events of Chugai Pharmaceutical. • 1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines • 1927: Start of the first own production • 1930: Salobrocanon, an analgesic (pain reliever ) and antipyretic, is launched • 1937: Calcium bromide production begins • 1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo • 1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga • 1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt • 1946: Construction of the plant in Kamagiishi • 1951: Guronsan, a drug to detoxify and restore liver function, is launched • 1952: Varsan, a perspiration insecticide, is launched • 1955: Chugai became a public company. • 1956: The stock is listed on the Tokyo Stock Exchange • 1957: Construction of the Ukima plant • 1960: Establishment of a research center (Takada Research Laboratory, Tokyo) • 1967: Foundation of Fukushima Kasai Co Ltd. • 1961 – Developed patents for synthesis of
vitamin A • 1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd. • 1971: Construction of the factory in Fujieda • 1975: Picibanil, a cancer drug, is launched • 1982: Opening of a branch in New York • 1986: Opening of a branch in London • 1989: Acquisition of Gen-Probe Incorporated (USA) • 1990: Epogin launched • 1995 – Released acute promyelocytic sphere of
leukemia drug treatment
Vesanoid • 1996 – Released anti-viral chemotherapeutic agent
Hivid (
HIV reverse transcriptase inhibitor) • 1997 – Released HIV protease inhibitor
Invirase • 1999 – Released
immunosuppressive agent
Cellcept • 2000 – Released
antiemetic drug
Kytril, developed to combat the side effects of
chemotherapy • 2001 – Produced anti-
influenza virus Tamiflu (Roche) • 2002: Start of the alliance with Roche • 2003: Xeloda, a cancer drug, is launched • 2005: Actemra launched • 2007: Copegus, an antiviral, Avastin, a cancer drug, and Tarceva, a cancer drug launched • 2011 – Produced
Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis • 2014: Launch of Kadcyla, a cancer drug, Chugai Pharma China Co Ltd. founded • 2015 – In March the company announced it would co-commercialise
Athersys's
stem cell therapy for
ischemic strokes in Japan. The deal could yield upwards of US$205 million. • 2016: Cooperation between Osaka University and Chugai • 2018: Tecentriq, a cancer drug, is launched • 2020 – FDA approved
satralizumab (Enspryng) for treatment of the
orphan disease neuromyelitis optica ==See also==